Organization
Grifols Therapeutics
12 clinical trials
1 abstract
Clinical trial
Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and AscitesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin DeficiencyStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin DeficiencyStatus: , Estimated PCD: 2028-09-01
Clinical trial
Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand DiseaseStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic LeukemiaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital MortalityStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary ImmunodeficiencyStatus: Completed, Estimated PCD: 2022-07-18
Clinical trial
A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin DeficiencyStatus: Recruiting, Estimated PCD: 2025-03-14
Clinical trial
A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care UnitStatus: Completed, Estimated PCD: 2021-08-25
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19Status: Terminated, Estimated PCD: 2021-12-13
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionStatus: Terminated, Estimated PCD: 2021-11-10
Clinical trial
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral ImmunodeficiencyStatus: Completed, Estimated PCD: 2022-03-28
Abstract
ADALIMUMAB THERAPEUTIC DRUG MONITORING TEST VALIDATED FOR MEASURING ABP 501 BIOSIMILAROrg: Progenika Biopharma, Grifols Therapeutics, RandD Spenshult, Derio, Spain,